During the past decade, Diablo Clinical Research conducted 100 clinical trials. In the 10-year time frame, 100 clinical trials started and 67 clinical trials were completed, i.e. on average, 67% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 34 clinical trials were completed. i.e. 81% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Diablo Clinical Research" #1 sponsor was "Pfizer" with 24 trials, followed by "Eli Lilly and Company" with 13 trials sponsored, "Medtronic Diabetes" with 11 trials sponsored, "Abbott Diabetes Care" with 10 trials sponsored and "AstraZeneca" with 10 trials sponsored. Other sponsors include 91 different institutions and companies that sponsored additional 70 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Diablo Clinical Research" #1 collaborator was "Pfizer" with 8 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 2 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Diablo Clinical Research" with 2 trials as a collaborator and "Integrated Medical Development" with 2 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Diablo Clinical Research" are "Diabetes Mellitus" (15 trials), "Type 1 Diabetes" (11 trials), "Diabetes Mellitus, Type 2" (10 trials), "Obesity" (10 trials) and "Type 1 Diabetes Mellitus" (9 trials). Many other conditions were trialed in "Diablo Clinical Research" in a lesser frequency.

Most popular intervention types in "Diablo Clinical Research" are "Drug" (94 trials), "Device" (42 trials), "Biological" (25 trials), "Other" (19 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (52 trials), "placebo" (5 trials), "AC2993" (4 trials), "BNT162b2" (4 trials) and "Rimegepant" (4 trials). Other intervention names were less common.

The vast majority of trials in "Diablo Clinical Research" are 150 trials for "All" genders, 7 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Diablo Clinical Research". undefined are not yet recruiting, 6 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 131 completed trials in Diablo Clinical Research, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Diablo Clinical Research, 14 "Phase 1" clinical trials were conducted, 47 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 30 trials that are defined as “Not Applicable".